Compare Novartis with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs SUN PHARMA - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS SUN PHARMA NOVARTIS/
SUN PHARMA
 
P/E (TTM) x 479.2 27.0 1,774.1% View Chart
P/BV x 27.8 2.3 1,191.5% View Chart
Dividend Yield % 1.6 0.7 240.1%  

Financials

 NOVARTIS   SUN PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-18
SUN PHARMA
Mar-19
NOVARTIS/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs758679 111.7%   
Low Rs579375 154.2%   
Sales per share (Unadj.) Rs228.4121.1 188.5%  
Earnings per share (Unadj.) Rs31.713.4 237.3%  
Cash flow per share (Unadj.) Rs32.820.7 158.4%  
Dividends per share (Unadj.) Rs10.002.75 363.6%  
Dividend yield (eoy) %1.50.5 286.7%  
Book value per share (Unadj.) Rs297.1172.6 172.2%  
Shares outstanding (eoy) m24.692,399.26 1.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.94.4 67.3%   
Avg P/E ratio x21.139.4 53.5%  
P/CF ratio (eoy) x20.425.5 80.1%  
Price / Book Value ratio x2.23.1 73.7%  
Dividend payout %31.520.6 153.3%   
Avg Mkt Cap Rs m16,5051,264,650 1.3%   
No. of employees `0000.717.5 3.8%   
Total wages/salary Rs m1,44559,671 2.4%   
Avg. sales/employee Rs Th8,441.316,608.1 50.8%   
Avg. wages/employee Rs Th2,163.63,409.6 63.5%   
Avg. net profit/employee Rs Th1,173.11,833.8 64.0%   
INCOME DATA
Net Sales Rs m5,639290,659 1.9%  
Other income Rs m1,71810,255 16.8%   
Total revenues Rs m7,357300,914 2.4%   
Gross profit Rs m-6363,076 -0.1%  
Depreciation Rs m2517,533 0.1%   
Interest Rs m555,553 1.0%   
Profit before tax Rs m1,57550,246 3.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-12,144 0.0%   
Tax Rs m7926,009 13.2%   
Profit after tax Rs m78432,093 2.4%  
Gross profit margin %-1.121.7 -5.1%  
Effective tax rate %50.312.0 420.2%   
Net profit margin %13.911.0 125.9%  
BALANCE SHEET DATA
Current assets Rs m9,522310,692 3.1%   
Current liabilities Rs m3,296173,396 1.9%   
Net working cap to sales %110.447.2 233.7%  
Current ratio x2.91.8 161.2%  
Inventory Days Days3799 37.0%  
Debtors Days Days28112 25.5%  
Net fixed assets Rs m46232,477 0.0%   
Share capital Rs m1232,399 5.1%   
"Free" reserves Rs m7,213411,691 1.8%   
Net worth Rs m7,336414,091 1.8%   
Long term debt Rs m015,226 0.0%   
Total assets Rs m11,105646,938 1.7%  
Interest coverage x29.510.0 293.4%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.4 113.0%   
Return on assets %7.65.8 129.8%  
Return on equity %10.77.8 137.8%  
Return on capital %22.210.2 218.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6166,025 0.1%   
Fx outflow Rs m3,63038,610 9.4%   
Net fx Rs m-3,57027,415 -13.0%   
CASH FLOW
From Operations Rs m1,61021,965 7.3%  
From Investments Rs m687-6,813 -10.1%  
From Financial Activity Rs m-2,677-27,305 9.8%  
Net Cashflow Rs m-380-8,442 4.5%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 5.1 39.0%  
FIIs % 1.6 23.0 7.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 8.3 259.0%  
Shareholders   41,647 133,026 31.3%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   ORCHID PHARMA LTD  CIPLA  ASTRAZENECA PHARMA  SUVEN LIFESCIENCES  STERLING BIOTECH  

Compare NOVARTIS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Oct 18, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS